Generic Name: Metaxalone
Class: Centrally Acting Skeletal Muscle Relaxants
VA Class: MS200
Chemical Name: 5-[(3,5-Dimethylphenoxy)methyl]-2-oxazolidinone
Molecular Formula: C12H15NO3
CAS Number: 1665-48-1
Centrally acting skeletal muscle relaxant.b
Uses for Skelaxin
If pharmacologic therapy is required for acute low back pain (usually a benign and self-limiting condition105 106 108 ), an analgesic (e.g., acetaminophen, NSAIA) generally is recommended.104 105 106 108 117 Skeletal muscle relaxants may be used alone or in combination with analgesics for short-term relief; however, consider high incidence of adverse effects (e.g., CNS effects).104 106 107 108 Use skeletal muscle relaxants with caution and weigh risks against benefits.104 106 107 108
Metaxalone is ineffective in the treatment of skeletal muscle hyperactivity secondary to chronic neurologic disorders (e.g., cerebral palsy) and other dyskinesias.b
Skelaxin Dosage and Administration
Manufacturer makes no specific recommendations regarding administration with meals; administration with high-fat meal increases absorption, but clinical importance is unknown.101 (See Food under Pharmacokinetics.)
Cautions for Skelaxin
Animal studies have failed to reveal fetal risk, but safe use during pregnancy has not been established; do not use in women who are or may become pregnant unless possible benefits outweigh potential risks.101 b
Common Adverse Effects
Interactions for Skelaxin
Specific Drugs and Laboratory Tests
Drug or Test
CNS depressants (e.g., alcohol, barbiturates)
Tests for glucose that utilize cupric sulfate (Benedict’s Solution, Clinitest, Fehling’s Solution)
Tests for glucose that utilize glucose oxidase (Clinistix, Diastix, Tes-Tape
Absolute bioavailability not determined.101
Usually within 1 hour.b
About 4–6 hours.b
High-fat meal delays time to peak plasma concentration by about 1–2 hours, increases peak plasma concentration by 178–194%, and increases extent of absorption (AUC) by 115–142%; clinical importance unknown.101
Precise mechanism of action is not known; does not directly relax skeletal muscle and has minimal skeletal muscle relaxant effect.101 b Beneficial effect probably is related to sedative properties.101 b
Unlike neuromuscular blocking agents, does not depress neuronal conduction, neuromuscular transmission, or muscle excitability.b
Advice to Patients
Potential for metaxalone to impair mental alertness or physical coordination, especially with concomitant use of alcohol or other CNS depressants; use caution when driving or operating machinery.101 b
Importance of informing patients of other important precautionary information. (See Cautions.)
Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.
This pricing information is subject to change at the sole discretion of DS Pharmacy. This pricing information was updated 02/2013. Actual costs to patients will vary depending on the use of specific retail or mail-order locations and health insurance copays.
Metaxalone 800MG Tablets (COREPHARMA LLC): 30/$119.99 or 90/$342.97
Skelaxin 800MG Tablets (KING PHARMA): 30/$141.74 or 90/$388.46
This report on medications is for your information only, and is not considered individual patient advice. Because of the changing nature of drug information, please consult your physician or pharmacist about specific clinical use.
The American Society of Health-System Pharmacists, Inc. and Drugs.com represent that the information provided hereunder was formulated with a reasonable standard of care, and in conformity with professional standards in the field. The American Society of Health-System Pharmacists, Inc. and Drugs.com make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information and specifically disclaims all such warranties. Users are advised that decisions regarding drug therapy are complex medical decisions requiring the independent, informed decision of an appropriate health care professional, and the information is provided for informational purposes only. The entire monograph for a drug should be reviewed for a thorough understanding of the drug's actions, uses and side effects. The American Society of Health-System Pharmacists, Inc. and Drugs.com do not endorse or recommend the use of any drug. The information is not a substitute for medical care.
AHFS Drug Information. © Copyright, 1959-2013, Selected Revisions November 18, 2012. American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland 20814.
Only references cited for selected revisions after 1984 are available electronically.
101. King Pharmaceuticals, Inc. Skelaxin (metaxalone) tablets prescribing information. Bristol, TN; 2003 Aug.
103. See S, Ginzburg R. Skeletal muscle relaxants. Pharmacotherapy. 2008; 28:207-13. [PubMed 18225966]
104. van Tulder MW, Touray T, Furlan AD et al. Muscle relaxants for non-specific low back pain. Cochrane Database Syst Rev. 2003; :CD004252. [PubMed 12804507]
105. Roelofs PD, Deyo RA, Koes BW et al. Non-steroidal anti-inflammatory drugs for low back pain. Cochrane Database Syst Rev. 2008; :CD000396. [PubMed 18253976]
106. Chou R, Qaseem A, Snow V et al. Diagnosis and treatment of low back pain: a joint clinical practice guideline from the American College of Physicians and the American Pain Society. Ann Intern Med. 2007; 147:478-91. [PubMed 17909209]
107. Institute for Clinical Systems Improvement. Health care guideline: adult acute and subacute low back pain. 15th ed. Bloomington, MN; 2012 Jan. From the ICSI website
108. Toth PP, Urtis J. Commonly used muscle relaxant therapies for acute low back pain: a review of carisoprodol, cyclobenzaprine hydrochloride, and metaxalone. Clin Ther. 2004; 26:1355-67. [PubMed 15530999]
117. Boothby LA, Doering PL, Hatton RC. Carisoprodol: a marginally effective skeletal muscle relaxant with serious abuse potential. Hosp Pharm. 2003; 38:337-45.
b. AHFS Drug Information 2006. McEvoy GK, ed. Metaxalone. Bethesda, MD: American Society of Health-System Pharmacists; 2006: 1391-2.